The InhibOx/NFCR Virtual Screening Service The website of our FP6 consortium InhibOx works closely with MolPort, a one-stop shop for compound acquisition
InhibOx is a computational drug discovery company
The company's primary objective is to develop novel and effective computational methods for drug discovery in order to improve the productivity of lead and candidate identification.
InhibOx was founded in 2001 by Professor W. Graham Richards, chairman of Chemistry at the University of Oxford and world leading computational chemist. The company grew from the outstandingly successful screen saver project which involved some 3.5 million personal computers in over 200 countries: the world's biggest computational chemistry experiment finding lead compounds to inhibit cancer targets, anthrax and smallpox. Subsequently, the company has built up a significant technology platform. Its main ongoing research activities comprise the development of entirely novel computational discovery methods and associated with this, the development of Scopius a very large database of chemical structures.
